Danavorexton

Danavorexton

Clinical data
Other names	TAK-925
Routes of administration	Intravenous
Drug class	Orexin receptor agonist
Identifiers
IUPAC name methyl (2R,3S)-3-(methanesulfonamido)-2-[(cis-4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate
CAS Number	2114324-48-8
PubChem CID	130310079
ChemSpider	68011464
UNII	1QMD83K4YN
ChEMBL	ChEMBL4650341
PDB ligand	A6F (PDBe, RCSB PDB)
Chemical and physical data
Formula	C21H32N2O5S
Molar mass	424.56 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@H](CC1)C1=CC=CC=C1
InChI InChI=1S/C21H32N2O5S/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22H,6,9-15H2,1-2H3/t17-,18+,19-,20-/m0/s1 Key:UXZAJSZFFARTEI-YRPNKDGESA-N

Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. It is related to another orexin receptor agonist known as TAK-994, the development of which was discontinued for safety reasons in October 2021.

See also

• Orexin receptor § Agonists
• List of investigational sleep drugs § Orexin receptor agonists

External links

• Danavorexton - AdisInsight